Extension program for people previously treated with belzutifan (MK-6482)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label extension enrolls participants who received belzutifan in qualifying parent trials to continue active treatment and long-term follow-up. The program collects safety data, duration of drug exposure, and survival outcomes while monitoring adverse events over time. Enrollment is limited to patients who are clinically stable or have resumed treatment after a temporary interruption in their parent study. The trial is sponsored by Merck and conducted at selected sites in the United States and Israel.

Why it matters

Who can join: the full rules

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable.
* Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll.

Where it's running

• Beth Israel Deaconess Medical Center ( Site 0107)
  Boston, Massachusetts, United States Recruiting
• Dana-Farber Cancer Institute ( Site 0105)
  Boston, Massachusetts, United States Recruiting
• Karmanos Cancer Center ( Site 0108)
  Detroit, Michigan, United States Recruiting
• Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100)
  Philadelphia, Pennsylvania, United States Recruiting
• UPMC Hillman Cancer Center ( Site 0101)
  Pittsburgh, Pennsylvania, United States Recruiting
• SCRI Oncology Partners ( Site 7000)
  Nashville, Tennessee, United States Recruiting

+7 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Toll Free Number
• Email: Trialsites@msd.com
• Phone: 1-888-577-8839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YKYY031 injection in advanced solid tumors in adults

  A phase 1 trial tests YKYY031 given by injection in adults with advanced solid tumors who have few other treatment options to see if it is safe and how it behaves in the body.

  Recruiting Phase 1 Youcare Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07631793

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• SLC-3010 plus axitinib versus axitinib alone for second-line treatment of advanced clear cell kidney cancer

  This trial tests whether adding SLC-3010 to axitinib works better than axitinib alone for adults with locally advanced or metastatic clear cell kidney cancer who need second-line treatment.

  Recruiting Phase 2 Yonsei University · Seoul · NCT07469683

• DEG6498 for people with advanced solid tumors

  This Phase 1 study will try once-daily oral DEG6498 in adults with advanced solid tumors, including BRAF-mutant cancers and liver cancer, who have no standard treatment to see if it is safe and shows signs of anti-tumor activity.

  Recruiting at 3 sites Phase 1 Degron Therapeutics Co. · Beijing, Beijing Municipality and 2 other locations · NCT07244835

• Real-world belzutifan outcomes and pharmacogenetics in von Hippel-Lindau syndrome

  This study will test belzutifan in people aged 14 and older with VHL syndrome to see how well it controls VHL-associated tumors, what side effects occur, and how genetic factors affect response.

  Recruiting Phase 2 AC Camargo Cancer Center · São Paulo, São Paulo · NCT07167329

• Registry for Rare Diseases

  This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT06573723

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.